Pharmacoeconomics 2017

1 papers

Top Research Directions

The 4 research directions with Pharmacoeconomics 2017 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Confounding by Indication in Observational Health Studies1100.0%
2Multi State Markov Models for Long Term Clinical Projections1100.0%
3Navigating Cost Effectiveness Thresholds for High Cost Therapies1100.0%
4Reconstructing Individual Patient Data from Survival Curves1100.0%

Download all directions as CSV

Institutions

Institutions credited by Pharmacoeconomics 2017 papers: a paper credits every institution named in its affiliations, once. 3 institutions share 1 credited papers.

#InstitutionPapersShare
1Cleveland Clinic 1100.0%
2Mayo Clinic 1100.0%
3Merck & Co., Inc., Rahway, NJ, USA (United States) 1100.0%

Download all institutions as CSV

About this data

Papers. Pharmacoeconomics 2017 lists 1 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 1 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-20 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Pharmacoeconomics 2017”, https://lacuna.tiptreesystems.com/venue/pharmacoeconomics/2017.

Impactful Papers

Papers from Pharmacoeconomics 2017 that shaped research clusters.

Foundational

Influential

Papers

Title
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States